Sutro Biopharma (STRO) Depreciation & Amortization (CF) (2017 - 2025)

Sutro Biopharma has disclosed Depreciation & Amortization (CF) across 9 years of filings, most recently posting $1.6 million for Q4 2025.

• Depreciation & Amortization (CF) for Q4 2025 came in at $1.6 million, down 14.35% year-over-year; the trailing twelve-month figure through Dec 2025 was $7.3 million (up 1.14% YoY), and the FY2025 annual result was $7.3 million, up 1.14% from the prior year.
• Depreciation & Amortization (CF) came in at $1.6 million for Q4 2025 at Sutro Biopharma, down from $1.9 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $1.9 million in Q1 2025 to a low of $1.1 million in Q3 2021.
• The 5-year median for Depreciation & Amortization (CF) is $1.7 million (2023), against an average of $1.6 million.
• Across the five-year window, Depreciation & Amortization (CF) grew 28.62% in 2022 and dropped 14.35% in 2025, its largest moves.
• Sutro Biopharma's Depreciation & Amortization (CF) stood at $1.3 million in 2021, then advanced by 21.01% to $1.5 million in 2022, then grew by 12.55% to $1.7 million in 2023, then climbed by 7.91% to $1.9 million in 2024, then fell by 14.35% to $1.6 million in 2025.
• The last three Depreciation & Amortization (CF) figures came in at $1.6 million (Q4 2025), $1.9 million (Q3 2025), and $1.9 million (Q2 2025), per Business Quant data.